Halozyme, Ventana Team Up for CDx Development
News May 28, 2015
Halozyme Therapeutics and Ventana Medical Systems, a Roche company, today announced a collaboration agreement to develop and commercialize a companion diagnostic assay for use with Halozyme's investigational new drug, PEGPH20.
Under the terms of the agreement, Ventana will develop an assay to identify high levels of hyaluronan (HA), a chain of sugars that can accumulate around cancer cells, using Halozyme's proprietary HA-binding protein. Ventana will ultimately be responsible for submitting the assay for regulatory approval in the US, Europe, and other countries as well as commercializing the assay.
Halozyme has announced plans for a global phase III clinical trial in 2016 to treat metastatic pancreatic cancer patients with high HA levels using PEGPH20 in combination with Abraxane and gemcitabine.
The assay could be the first companion diagnostic assay for pancreatic cancer, Ventana Companion Diagnostics VP Doug Ward said in a statement.
Financial details of the agreement were not disclosed.
Last month Ventana signed a master collaboration agreement with Astellas to develop companion diagnostics for the Japanese drug maker. In January, Ventana completed a premarket approval application with the US Food and Drug Administration for an ALK companion diagnostic, but did not disclose its drug partner.
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Simple Sugar Prevents Neurodegeneration in Lysosomal Storage DiseaseNews
New therapeutic approach may one day delay neurodegeneration typical of a disease called mucopolysaccharidoses IIIB (MPS IIIB)READ MORE
Penn Medicine Biochemist Receives Major Award for Research on Epigenetic Protein Modifications via Mass SpecNews
Benjamin A.Garcia, PhD, an expert in quantitative proteomics and Presidential Professor of Biochemistry and Biophysics in the Perelman School of Medicine at the University of Pennsylvania, has been awarded the Biemann Medal by the American Society for Mass Spectrometry (ASMS). The early-career award recognizes significant achievement in basic or applied mass spectrometry.